Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 21;12(9):2370. doi: 10.3390/cancers12092370

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Selective cellular uptake of CAPE-MotAb in cancer cells by targeting mortalin. (A) Fluorescence microscopy images of A549 and MRC5 cells treated with CAPE-PEG and CAPE-MotAb followed by staining with Alexa Fluor^TM 594-tagged secondary antibody. The nuclei were stained with Hoechst. Higher cellular uptake efficiency of CAPE-MotAb was observed in A549 cells. (B) Quantitation of mortalin expression from fluorescence images (mean ± SD, n = 3), *** p < 0.001 (Student’s t-test). (C) Quantitative analysis of cellular uptake of CAPE-PEG and CAPE-MotAb in A549 and MRC5 cells (mean ± SD, n = 3), *** p < 0.001 (Student’s t-test). CAPE-MotAb treated A549 cells exhibited higher CAPE accumulation as compared to MRC5 cells treated with the same nanoparticles. A549 and MRC5 cells for all above experiments were treated with an equivalent dose of CAPE (20 µg/mL) for 12 h.